ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune
monitoring products and services, has launched CFSE T cell proliferation
assays for immunogenicity risk assessment. The new highly sensitive
assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of
tools used in the design and selection of biological drug leads at the
Combined with ProImmune’s unique cell-free HLA-peptide binding assays
for more than 50 class II HLA alleles, these new assays enable the
creation of a detailed profile of the helper T cell immune response to
one or more drug leads.
Unlike traditional assays, which are based on radioactive thymidine
incorporation, ProImmune’s new assays utilise powerful flow cytometry
methods, enabling accurate determination of the percentage of
proliferating CD4-positive cells and detailed phenotyping of T cell
responses with significantly improved overall sensitivity.
Dr. Nikolai Schwabe, CEO of ProImmune, said: "Our customers have come to
expect ProImmune to deliver technology leadership without compromise.
The launch of our CFSE T cell proliferation assays joins with our
unequalled capability in class II HLA binding assays, delivering the
most powerful in vitro assay platform on the market for assessing
drug immunogenicity risk.”